

MT2023-51 A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed diagnosis of metastatic Stage IV NSCLC without specific genomic alterations - if the tumor has a treatable mutation(s) (other than EGFR, ALK, or ROS1 genomic alterations), 1 additional line of therapy with the appropriate targeted therapy is required - may be restricted from strenuous activity but walking and able to carry out work of a light or sedentary nature, e.g., light house work, office work - patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy - see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria

Exclusion Criteria:

- on systemic steroid therapy ≥ 10 mg/day of prednisone or equivalent - have any form of primary immunodeficiency - had another primary cancer within the previous 3 years

Conditions & Interventions

Interventions:

Biological: LN-145, Biological: LN-145

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Metastatic Non Small Cell Lung Cancer, NSCLC

More Information

Description: This study is being done to learn more about the efficacy and safety of LN-145 in participants with metastatic stage IV non-small cell lung cancer.

Study Contact: Amanda Garcia - garc0276@umn.edu

Principal Investigator: Benjamin Manning

Phase: PHASE2

IRB

Number: STUDY00022060

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.